Clinical Trial Update: Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer [Phase 1]

View source ↗

Summary

The document reports the completion of a Phase 1 trial evaluating pretargeted radioimmunotherapy using an anti-CEA bispecific antibody and Lu-177–labeled peptid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Anti-CEA bispecific antibody
• Lu-177-labeled peptide (Lutetium-177-labeled peptide)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Colorectal Neoplasms | Phase 1 | Status: COMPLETED